12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting bacterial RelA to enhance isoniazid sensitivity in tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Cell culture and mouse studies suggest inhibiting M. tuberculosis RelA could help treat chronic-phase tuberculosis (TB), which is resistant to the generic antimalarial isoniazid. In an M. tuberculosis culture-based...
07:00 , Mar 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Guanosine 5'-diphosphate 3'-diphosphate (ppGpp); guanosine 5'-triphosphate 3'-diphosphate (pppGpp)

Infectious disease INDICATION: Bacterial infection In vitro and insect studies suggest that D-enantiomeric anti-microbial peptides inhibiting ppGpp and pppGpp could help treat bacterial infections by eliminating biofilms. Chemical synthesis and in vitro testing of a...
07:00 , Jun 26, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Guanosine 5ʹ-diphosphate 3ʹ-diphosphate (ppGpp); guanosine 5ʹ-triphosphate 3ʹ-diphosphate (pppGpp) In vitro studies suggest inhibiting ppGpp and pppGpp could help treat bacterial infections by...
07:00 , Oct 11, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Gram-positive bacterial infection GTP pyrophosphokinase (relA) In vitro studies identified an inhibitor of relA that could help treat Gram-positive bacterial infections. relA synthesizes (p)ppGpp,...
08:00 , Feb 7, 2000 |  BC Week In Review  |  Company News

Questcor, Dainippon deal

QSC and Dainippon mutually terminated a 1998 anti-bacterial research collaboration and transferred all related drug discovery research from QSC to Dainippon (see BioCentury, Feb. 2, 1998). Under the termination, QSC granted Dainippon an exclusive worldwide...